XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp.
- ISIN: CA98421R1055
- Land: .
Nachricht vom 13.08.2019 | 17:55
XPhyto Therapeutics Commences Trading on the Frankfurt Stock Exchange
DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) ("XPhyto" or the "Company") is pleased to announce that its common shares have commenced trading today on the Frankfurt Stock Exchange (the "FSE") under the ticker symbol "4XT".
"Given XPhyto's German cannabis licence and its commitment to building import and distribution capability in the country, a Frankfurt listing was a logical choice," noted Hugh Rogers, CEO of XPhyto. "We are excited to help facilitate the opportunity for German investors to participate in their own emerging cannabis industry. XPhyto considers itself one of the only German focused cannabis companies in the world."
The FSE is the largest of seven stock exchanges in Germany and one of the ten largest stock exchanges in the world. There are over 1.4 million securities tradeable on the FSE including stocks, bonds, ETFs, ETCs, ETNs, funds, warrants and certificates. The FSE is regulated under German law.
About XPhyto Therapeutics Corp.
XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto's 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). XPhyto is pursuing additional opportunities in Germany including cultivation, processing, manufacturing, import, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability.
For further information, please contact:Hugh Rogers
CEO & Director
Forward looking statements
This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building an industry leading medical cannabis company Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not derive the expected, or any, benefits from the Licence; that the Company may be unable to scale its business; product liability risks; frequent changes to cannabis regulations in Canada and internationally; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46899
Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/46899
|Company:||XPhyto Therapeutics Corp.|
|EQS News ID:||856939|
|End of News||DGAP News Service|